Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...
The trial met its primary endpoint, showing a statistically significant improvement in median overall survival.
NVCR earnings call for the period ending September 30, 2024.
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.48%. Stocks today are mixed....
December S&P 500 E-Mini futures (ESZ24) are up +0.03%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning, steadying after yesterday’s slump, while investors awaited the next round...
Investors found the announced changes to the company's C-suite unsettling.
Someone's gotta make 'em, and someone's gotta buy 'em.
NVCR earnings call for the period ending June 30, 2024.